<p>Akero Therapeutics Inc. held a special meeting of stockholders on December 2, 2025. At the meeting, stockholders approved the proposed acquisition of Akero Therapeutics Inc. by Novo Nordisk A/S, including the related merger agreement and contingent value rights agreement. All proposals presented at the meeting received the necessary approval from stockholders. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akero Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-25-044131), on December 03, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

AKRO

<p>Akero Therapeutics Inc. held a special shareholder meeting on December 2, 2025, where stockholders approved its acquisition by Novo Nordisk A/S, including the merger and contingent value rights agreements. All proposals received necessary approval.</p>

Akero Therapeutics Inc. Held Special Shareholder Meeting